Pirtobrutinib, sold under the brand name Jaypirca, is an anticancer medication that is used to treat mantle cell lymphoma. It inhibits B cell lymphocyte...
17 KB (1,165 words) - 07:22, 22 August 2024
of recurrent or refractory primary central nervous system lymphoma. Pirtobrutinib (Jaypirca), a reversible (non-covalent) inhibitor of BTK, for mantle...
22 KB (2,389 words) - 06:43, 22 April 2024
mantle cell lymphoma who have received at least one prior therapy. Pirtobrutinib (Jaypirca) was approved for medical use in the United States in January...
41 KB (4,549 words) - 08:59, 25 January 2024
Cobimetinib Selumetinib Trametinib EML4-ALK Crizotinib Entrectinib Lorlatinib Bruton's Acalabrutinib Ibrutinib Orelabrutinib Pirtobrutinib Zanubrutinib...
12 KB (794 words) - 16:43, 28 August 2024
L01EL02 Acalabrutinib L01EL03 Zanubrutinib L01EL04 Orelabrutinib L01EL05 Pirtobrutinib L01EM01 Idelalisib L01EM02 Copanlisib L01EM03 Alpelisib L01EM04 Duvelisib...
12 KB (877 words) - 15:36, 25 January 2024
Cobimetinib Selumetinib Trametinib EML4-ALK Crizotinib Entrectinib Lorlatinib Bruton's Acalabrutinib Ibrutinib Orelabrutinib Pirtobrutinib Zanubrutinib...
12 KB (758 words) - 23:46, 14 March 2024